Léa Chantal Tran

Léa Chantal Tran

Auto-generated profile, based on publicly available information

Léa Chantal Tran

Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
LMLucie Marousez
Lucie Marousez
NSnorbert sprenger
norbert sprenger
MLMarie De Lamballerie
Marie De Lamballerie
SJSarahi Jaramillo-Ortiz
Sarahi Jaramillo-Ortiz
LTLéa Tran
Léa Tran
Jean LesageJean Lesage
Jean Lesage

16 July 2022 in The Journal of Pediatrics
Verified
Journal Article
Closed access
ANAudrey Nicolas
Audrey Nicolas
MAMadeleine Aumar
Madeleine Aumar
LTLéa Chantal Tran
Léa Chantal Tran
ATAlice Tiret
Alice Tiret
RDRémi Duclaux-Loras
Rémi Duclaux-Loras
FGfréderic gottrand
fréderic gottrand

27 January 2024 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
LTLéa Chantal Tran
Léa Chantal Tran
LMLucie Marousez
Lucie Marousez
EMEdwina Micours
Edwina Micours
MLMarie De Lamballerie
Marie De Lamballerie
LTLou Thys
Lou Thys
MTMarie Titécat
Marie Titécat

16 June 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
LMLucie Marousez
Lucie Marousez
LTLéa Chantal Tran
Léa Chantal Tran
EMEdwina Micours
Edwina Micours
MAMatthieu Antoine
Matthieu Antoine
FGfréderic gottrand
fréderic gottrand
DLDelphine Ley
Delphine Ley
Background: An inadequate perinatal nutritional environment can alter the maturation of the intestinal barrier and promote long-term pathologies such as metabolic syndrome or chronic intestinal diseases. The intestinal microbiota seems to play a determining role in the development of the intestinal barrier. In the present study, we investigated the impact of consuming an early postnatal prebiotic fiber (PF) on growth, intestinal morphology and the microbiota at weaning in postnatal-growth-restricted mice (PNGR). Methods: Large litters (15 pups/mother) were generated from FVB/NRj mice to induce PNGR at postnatal day 4 (PN4) and compared to control litters (CTRL, 8 pups/mother). PF (a resistant dextrin) or water was orally administered once daily to the pups from PN8 to PN20 (3.5 g/kg/day). Intestinal morphology was evaluated at weaning (PN21) using the ileum and colon. Microbial colonization and short-chain fatty acid (SCFA) production were investigated using fecal and cecal contents. Results: At weaning, the PNGR mice showed decreased body weight and ileal crypt depth compared to the CTRL. The PNGR microbiota was associated with decreased proportions of the Lachnospiraceae and Oscillospiraceae families and the presence of the Akkermansia family and Enterococcus genus compared to the CTRL pups. The propionate concentrations were also increased with PNGR. While PF supplementation did not impact intestinal morphology in the PNGR pups, the proportions of the Bacteroides and Parabacteroides genera were enriched, but the proportion of the Proteobacteria phylum was reduced. In the CTRL pups, the Akkermansia genus (Verrucomicrobiota phylum) was present in the PF-supplemented CTRL pups compared to the water-supplemented ones. Conclusions: PNGR alters intestinal crypt maturation in the ileum at weaning and gut microbiota colonization. Our data support the notion that PF supplementation might improve gut microbiota establishment during the early postnatal period.

18 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
CLCarneiro Lionel
Carneiro Lionel
LMLucie Marousez
Lucie Marousez
MHMatthias Van Hul
Matthias Van Hul
LTLéa Chantal Tran
Léa Chantal Tran
MLMarie De Lamballerie
Marie De Lamballerie
Jean LesageJean Lesage
Jean Lesage
Background: Human milk banks (HMBs) provide sterilized donor milk (DM) for the feeding of preterm infants. Most HMBs use the standard method of Holder pasteurization (HoP) performed by heating DM at 62.5 °C for 30 min. High hydrostatic pressure (HHP) processing has been proposed as an alternative to HoP. This study aims to evaluate intestinal barrier integrity and microbiota composition in adult mice subjected to a chronic oral administration of HoP- or HHP-DM. Methods: Mice were treated by daily gavages with HoP- or HHP-DM over seven days. Intestinal barrier integrity was assessed through in vivo 4 kDa FITC–dextran permeability assay and mRNA expression of several tight junctions and mucins in ileum and colon. Cecal short chain fatty acids (SCFAs) and microbiota were analyzed. Results: HHP-DM mice displayed decreased intestinal permeability to FITC–dextran and increased ileal mRNA expression levels of two tight junctions (Ocln and Cdh1) and Muc2. In the colon, mRNA expression levels of two tight junctions (Cdh1 and Tjp1) and of two mucins (Muc2 and Muc4) were decreased in HHP-DM mice. Cecal SCFAs and microbiota were not different between groups. Conclusions: HHP processing of DM reinforces intestinal barrier integrity in vivo without affecting gut microbiota and SCFAs production. This study reinforces previous findings showing that DM sterilization through HHP might be beneficial for the intestinal maturation of preterm infants compared with the use of HoP for the treatment of DM.

7 June 2025 in Pediatric Research
Verified
Journal Article
Open access
PDF file
JSJuliette Soudant
Juliette Soudant
SLStéphanie Lejeune
Stéphanie Lejeune
MAMadeleine Aumar
Madeleine Aumar
NCNicolas Caron
Nicolas Caron
HLHélène Lengline
Hélène Lengline
LTLéa Chantal Tran
Léa Chantal Tran
Background: No biological treatment has been approved for pediatric eosinophilic esophagitis (EoE) in France. For patients refractory to conventional treatments, although compassionate use of monoclonal antibodies has developed, experience remains limited. Methods: We conducted a national multicenter study across French pediatric tertiary care centers where children (younger than 18 years) who presented with EoE were treated with biological therapies between January 2015 and December 2023. The main objective was to characterize this patient population, and the indications for prescribing biologics. The secondary goals were to assess these patients’ clinical, endoscopic, and histologic finding, as well as patient tolerance, and to compare our cohort at baseline with pediatric patients from two European registers of EoE treated with conventional therapies. Results: Thirty-six patients were prescribed 37 biologics (omalizumab, n = 1; mepolizumab, n = 6; dupilumab, n = 30). At diagnosis, the mean patient age was 7.4 (±4.4) years, and most patients had at least one atopic comorbidity (91.7%, n = 33). Failure of first-line treatments was the main reason for starting biological therapy (75.7%, n = 28), prescribed as compassionate use (54.1%, n = 20). Dupilumab showed significant clinical (48%, p < 0.01) and histological (82.6%, p < 0.01) improvement. Compared with children treated with conventional therapies, patients in our cohort at baseline presented significantly more asthma, food allergies, and atopic dermatitis, as well as more fibrostenotic phenotype and digestive symptoms. No severe side effect was reported within a 6–12-month follow-up. Conclusion: Dupilumab is the most frequently prescribed, and appears to be the most effective biotherapy, regarding clinical and histologic remission. All biologics were well-tolerated. Impact: Pending marketing authorization, biological therapies for pediatric eosinophilic esophagitis are mainly prescribed after failure of first-line treatments and on a compassionate basis in France. Dupilumab is the biotherapy most frequently used, is associated with clinical and histological efficacy and is well-tolerated. Children and adolescents requiring biologics appear to be younger and more severe at diagnosis than naive pediatric patients in Europeans registries.